[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-rectum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-rectum":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,122,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100369819","phase-3-standard-dose-versus-high-dose-of-radiotherapy-in-rectal-preservation-with-chemo-radiotherapy-in-rectal-cancer-patients-100369819",false,"NCT04095299","Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients","Randomized Trial of Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy to Patients With Early Low and Mid Rectal Cancer: The Watchful Waiting 3 Trial (WW3)","WW3","Inclusion Criteria:\n\n* Histopathologically verified adenocarcinoma of the rectum\n* MDT conference finds patient a candidate for rectal resection\n* Clinical tumor category cT1-3\n* MRI findings\n\n  * Maximal cross-sectional size of 4.5 cm (axial plane relative to the rectum)\n  * Lowest edge of tumor located at or below the peritoneal reflection on MRI\n* Performance status 0-2\n* Age ≥ 18 years\n* Eligible for radiotherapy and capecitabine according to investigator, including\n\n  * Adequate function of bone marrow (neutrophils ≥ 1.5 x 10\\^9\u002Fl and thrombocytes ≥ 100 x 10\\^9\u002Fl)\n  * Adequate function of liver (ALAT \\\u003C 2.5 x upper limit of normal, bilirubin \\\u003C 2.5 x upper limit of normal)\n  * Adequate kidney function (Serum creatinine \\\u003C 1.5 x upper limit of normal or measured GFR \\> 30 ml\u002Fmin)\n* Fertile women must present a negative pregnancy test and use secure contraceptives during and three months after treatment\n* Written and orally informed consent\n\nExclusion Criteria:\n\n* Previous surgical treatment of the present cancer, including transanal excision of tumor\n* Other malignant disease within the past five years except non-melanoma skin cancer and premalignant lesions such as carcinoma in situ\n* Distant metastases verified by imaging or biopsy, i.e. cM1\n* Previous radiation treatment of the pelvis\n* Pregnant or breastfeeding women.\n* Existing colostomy or ileostomy","ALL","18 Years",{"count":20,"type":21},162,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy. Prospective trials, including the previous Danish Watchful Waiting trials (NCT00952926, NCT02438839) in early rectal cancer have demonstrated high levels of organ preservation with dose-escalation, but it is unclear whether this was primarily due to tumor stage or dose level.\n\nThe aim of the present study is to investigate if a higher dose of radiotherapy is superior compared to a standard dose in patients with early rectal cancer undergoing chemoradiotherapy with curative intent.",[27],"Cancer of Rectum","RECRUITING","2026-01-06",{"date":31,"type":32},"2026-01-08","ACTUAL",{"date":34,"type":32},"2020-01-20",{"date":36,"type":21},"2033-12",{"name":38,"class":39},"Vejle Hospital","OTHER",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":95,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":48,"type":21},50000,"36 Months","OBSERVATIONAL","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[53,54,55,56,57,58,27,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[96,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":113,"type":32},"2025-10-28",{"date":115,"type":32},"2018-01-01",{"date":117,"type":21},"2040-06",{"name":119,"class":120},"Massive Bio, Inc.","INDUSTRY",68,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":40},"100495530","phase-2-immunotherapy-in-patients-with-early-dmmr-rectal-cancer-100495530","NCT05732389","Immunotherapy in Patients With Early dMMR Rectal Cancer","RESET-R","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically verified non-metastatic rectal cancer stage 1-3.\n* No indication for local therapy like TEM.\n* Histologically verified dMMR or MSI.\n* Performance status (WHO) of 0-1.\n* No previous chemotherapy, radiotherapy or immunotherapy for colorectal cancer\n* Adequate haematological function defined as neutrophils ≥ 1.5 x 109\u002Fl and platelets ≥ 100 x 109\u002Fl.\n* Adequate organ function (bilirubin ≤ 1.5 x UNL (upper normal limit), GFR (may be calculated) \\> 30 ml\u002Fmin.\n* Women of childbearing potential must have been tested negative in a serum pregnancy test within five days prior to registration. Fertile patients must agree to use a highly effective method of birth control. (i.e., pregnancy rate of less than 1 % per year) (Appendix 1) during the study and for six months after the discontinuation of study medication.\n* Has provided written informed consent prior to performance of any study procedure.\n* Written informed consent must be obtained according to the local Ethics Committee requirements.\n\nExclusion Criteria:\n\n* Any other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.\n* Concomitant use of systemic glucocorticoids more than the equivalent dose to tablet prednisolone 10 mg\u002Fday. Treatment with systemic glucocorticoids must end no later than two weeks before inclusion.\n* Subjects with active, known, or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.\n* Known allergy or intolerance to any of the drugs used (nivolumab and ipilimumab).",{"count":130,"type":21},39,[132],"PHASE2","The purpose of this investigator-initiated, multicenter phase II trial is to evaluate the efficacy and tolerability of nivolumab and ipilimumab in patients with stage 1-3 MSI\u002FdMMR rectal cancer.\n\nThe primary objective is:\n\nNumber of patients with complete clinical response after one or two cycles of immunotherapy.\n\nPatients will be treated with 1 or 2 cycles of combination immunotherapy:\n\nCycle 1: Nivolumab 3 mg\u002Fkg days 1 and 15 \\& ipilimumab 1 mg\u002Fkg day 1 Cycle 2: Nivolumab 3 mg\u002Fkg days 50 and 65 \\& ipilimumab 1 mg\u002Fkg day 50",[27],"2025-08-01",{"date":137,"type":32},"2025-08-07",{"date":139,"type":32},"2023-02-01",{"date":141,"type":21},"2052-02",{"name":143,"class":39},"Odense University Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100329789","biomarkers-for-predicting-neoadjuvant-chemoradio-resistance-for-middle-low-advanced-rectal-cancer-100329789","NCT03573791","Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer","Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.","Inclusion Criteria:\n\n* Histopathology proved to be adenocarcinoma of the rectum.\n* The edge of tumor is within 12cm of anus margin.\n* According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2.\n* There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy.\n* Understand and agree to sign the informed consent for the study.\n\nExclusion Criteria:\n\n* With intestinal obstruction or impending obstruction, or perforation.\n* With other malignancies occurred within 5 years.","75 Years",{"count":153,"type":21},152,"Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.",[156,27,157,158,159,160,161],"Rectal Cancer","Cancer of the Rectum","Neoplasms, Rectal","Rectal Tumors","Rectum Cancer","Rectum Neoplasms","2025-03-25",{"date":164,"type":32},"2025-03-30",{"date":166,"type":32},"2018-05-21",{"date":168,"type":21},"2027-05-21",{"name":170,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2]